Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptinyx Inc. stock logo
APTX
Aptinyx
$0.10
$0.08
$0.01
$0.72
N/A1.271.32 million shs231,126 shs
ARAVIVE, INC stock logo
ARAV
ARAVIVE
$0.04
$0.04
$0.04
$2.46
$2.95MN/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
$9.36
$9.36
$9.10
$12.00
$167.08M0.53600 shsN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
$5.47
$5.47
$5.47
$352.00
$127.45M2.46279 shsN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
$2.10
+1.4%
$2.03
$1.15
$42.20
$101.45M-2.042.86 million shs653,335 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptinyx Inc. stock logo
APTX
Aptinyx
0.00%0.00%0.00%0.00%0.00%
ARAVIVE, INC stock logo
ARAV
ARAVIVE
0.00%0.00%0.00%0.00%0.00%
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
0.00%0.00%0.00%0.00%-22.00%
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
0.00%0.00%0.00%0.00%0.00%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
+0.49%-5.48%+0.98%+43.75%-84.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/AN/AN/AN/AN/AN/A
ARAVIVE, INC stock logo
ARAV
ARAVIVE
N/AN/AN/AN/AN/AN/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
4.1632 of 5 stars
3.33.00.04.72.70.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptinyx Inc. stock logo
APTX
Aptinyx
0.00
N/AN/AN/A
ARAVIVE, INC stock logo
ARAV
ARAVIVE
0.00
N/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
0.00
N/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
0.00
N/AN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
2.50
Moderate Buy$54.502,495.24% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptinyx Inc. stock logo
APTX
Aptinyx
$1MN/AN/AN/A$0.57 per shareN/A
ARAVIVE, INC stock logo
ARAV
ARAVIVE
$9.14M0.32N/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
$6.82M24.50N/AN/A$0.21 per share44.57
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
$36.55M3.49N/AN/A($67.63) per share-0.08
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/A$3.03 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptinyx Inc. stock logo
APTX
Aptinyx
-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/A
ARAVIVE, INC stock logo
ARAV
ARAVIVE
-$76.32MN/A0.00N/AN/AN/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
-$17.63MN/A0.00N/AN/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
-$150.73MN/A0.00N/A-894.02%-3,350.55%-67.76%N/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-$24.34M-$1.50N/AN/AN/AN/A-87.72%-72.05%8/14/2025 (Estimated)

Latest ARAV, NWPHF, PFSCF, SAVA, and APTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A-$0.48N/A-$0.48N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/AN/AN/A
ARAVIVE, INC stock logo
ARAV
ARAVIVE
N/AN/AN/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/AN/AN/AN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/A
ARAVIVE, INC stock logo
ARAV
ARAVIVE
N/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/A
0.95
0.71
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A
9.08
9.08

Institutional Ownership

CompanyInstitutional Ownership
Aptinyx Inc. stock logo
APTX
Aptinyx
N/A
ARAVIVE, INC stock logo
ARAV
ARAVIVE
35.80%
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
0.10%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
38.05%

Insider Ownership

CompanyInsider Ownership
Aptinyx Inc. stock logo
APTX
Aptinyx
10.97%
ARAVIVE, INC stock logo
ARAV
ARAVIVE
60.40%
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
2.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptinyx Inc. stock logo
APTX
Aptinyx
12N/AN/ANot Optionable
ARAVIVE, INC stock logo
ARAV
ARAVIVE
2073.56 million29.13 millionNo Data
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
2217.85 millionN/ANot Optionable
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
5023.31 millionN/ANot Optionable
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
3048.31 million47.15 millionOptionable

Recent News About These Companies

Cassava Sciences Inc.
Cassava takes next step for African AI

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aptinyx stock logo

Aptinyx NASDAQ:APTX

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

ARAVIVE stock logo

ARAVIVE NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 07/16/2025

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Newron Pharmaceuticals stock logo

Newron Pharmaceuticals OTCMKTS:NWPHF

$9.36 0.00 (0.00%)
As of 07/11/2025

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

ProMetic Life Sciences stock logo

ProMetic Life Sciences OTCMKTS:PFSCF

$5.47 0.00 (0.00%)
As of 11/18/2019

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

Cassava Sciences stock logo

Cassava Sciences NASDAQ:SAVA

$2.10 +0.03 (+1.45%)
Closing price 04:00 PM Eastern
Extended Trading
$2.09 -0.01 (-0.48%)
As of 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.